Sign In
Buy MRK
$115.49
+0.320 (+0.278%)
At Close: Jun 17, 2026
Is the Best-Performing Dow Stock of the Past Year a Buy?
09:45am, Tuesday, 21'st Mar 2023
Merck is still benefitting from its crown jewel, cancer drug Keytruda. However, the company's lineup and pipeline extend far beyond this medicine.
7 Defensive Stocks to Buy During This Chaotic Spell
06:31pm, Monday, 20'th Mar 2023
While it's always a good idea to balance your portfolio with defensive stocks, the present chaos dramatically incentivizes this subsegment. As you've no doubt heard, the U.S. and the rest of the world
Merck (MRK) Stock Up 31.6% in a Year: What Awaits in 2023?
07:42am, Monday, 20'th Mar 2023
Strong sales of key products like Keytruda and Gardasil and positive pipeline/regulatory developments should keep Merck's (MRK) stock afloat in 2023.
Could This Be Merck's Next Blockbuster Drug?
09:20am, Saturday, 18'th Mar 2023
Merck's hypercholesterolemia medicine could save the lives of countless patients in the long run. Annual sales could reach well into the billions for the drug.
Merck's (MRK) Co-formulation Therapy Fails Lung Cancer Study
02:31pm, Friday, 17'th Mar 2023
Data from a mid-stage study showed that Merck's (MRK) MK-7684A did not improve progression-free survival as a potential treatment for patients with metastatic non-small cell lung cancer.
Merck's combination therapy in lung cancer fails a Phase 2 clinical trial
08:08am, Friday, 17'th Mar 2023
Merck & Co. Inc. MRK, -0.27% said late Thursday that its combination therapy of vibostolimab and Keytruda did not outperform chemotherapy in a Phase 2 clinical trial of patients with metastatic non-sm
4 Factor Dividend Growth Portfolio - First Insight
03:21am, Thursday, 16'th Mar 2023
The 4-factor dividend growth portfolio was launched on November 1st, 2022, and is performing quite well. The portfolio lost by 34 bps to the S&P 500 Total Return during the month of February.
Merck & Co., Inc. (MRK) Barclays 2023 Global Healthcare Conference Transcript
08:10pm, Wednesday, 15'th Mar 2023
Merck & Co., Inc. (NYSE:MRK ) Barclays 2023 Global Healthcare Conference March 15, 2023 2:35 PM ET Company Participants Jannie Oosthuizen – President-Merck Human Health U.S. Peter Dannenbaum – Vic
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
10:44am, Tuesday, 14'th Mar 2023
Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
MDA Breakout Stocks/ETFs Week 11 - March 2023: High-Frequency Gainers To Give You An Edge
08:03am, Sunday, 12'th Mar 2023
Two new Breakout Stocks for Week 11 with better than 10% short-term upside and Dow 30 Picks. Average cumulative returns for 2023 are +37.6% YTD. The Momentum Gauges® continued negative with bear fund
Merck (MRK) Reports Detailed Data From PAH Study on Sotatercept
09:02am, Wednesday, 08'th Mar 2023
Merck & Co. (MRK) announces detailed data from the phase III STELLAR study of sotatercept for the treatment of pulmonary arterial hypertension in adults.
Merck to Present at the Barclays 2023 Global Healthcare Conference
06:45am, Wednesday, 08'th Mar 2023
RAHWAY, N.J.
Beat the Dow Jones With This Unstoppable Dividend Stock
05:12am, Wednesday, 08'th Mar 2023
The company has more than 30 phase 3 trials in the works. Merck had seven therapies with sales of $1 billion in 2022.
Keytruda Who? Merck Nears Breakout On $10 Billion Sales Potential For Heart Drugs
10:14am, Tuesday, 07'th Mar 2023
Two of Merck's new drugs could generate north of $10 billion in peak sales, an analyst said Tuesday. The post Keytruda Who?
Merck & Co., Inc. (MRK) Presents at Special Call (Investor Event at ACC.23/WCC) (Transcript)
04:19am, Tuesday, 07'th Mar 2023
Merck & Co., Inc. (NYSE:MRK ) Special Call (Investor Event at ACC.23/WCC) March 6, 2023 7:00 PM ET Company Participants Peter Dannenbaum - VP, IR Dean Li - President, Merck Research Laboratories Joerg
